{
    "nct_id": "NCT03327649",
    "official_title": "Neuromodulation of Inflammation to Treat Heart Failure With Preserved Ejection Fraction",
    "inclusion_criteria": "* HFpEF, defined as signs and symptoms of heart failure, LV ejection fraction ≥50%, brain natriuretic peptide ≥35pg/mL and echocardiographic evidence of diastolic dysfunction (left atrial volume index ≥34mL/m2, mitral E-wave velocity/mitral annular velocity ratio [E/e']≥13 and e'<9cm/s) plus 2 of the following 4 comorbidities:\n\n  * age ≥ 65,\n  * diabetes,\n  * hypertension and\n  * obesity, defined as body mass index ≥30kg/m2\nHealthy volunteers allowed\nMust have minimum age of 21 Years\nMust have maximum age of 90 Years",
    "exclusion_criteria": "* LV ejection fraction <40%\n* significant valvular disorder (i.e., prosthetic valve or hemodynamically significant valvular diseases)\n* recent (<6 months) stroke, myocardial infarction or hospitalization for heart failure\n* severe heart failure (class III or IV)\n* end stage kidney disease\n* recurrent vasovagal syncope\n* history of vagotomy\n* pregnancy\n* sick sinus syndrome and 2nd or 3rd degree AV block (without a pacemaker).",
    "miscellaneous_criteria": ""
}